Selective Bcl-2 inhibition promotes hematopoietic chimerism and allograft tolerance without myelosuppression in nonhuman primates
Science Translational Medicine · 2023
DOI: 10.1126/scitranslmed.add5318 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2023. Verfasst von Hajime Sasaki und 21 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Department of Surgery, Harvard Medical School, Boston, MA 02114, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Kidney Transplantation. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Hematopoietic stem cell transplantation (HSCT) has many potential applications beyond current standard indications, including treatment of autoimmune disease, gene therapy, and transplant tolerance induction. However, severe myelosuppression and other toxicities after myeloablative conditioning regimens have hampered wider clinical use. To achieve donor hematopoietic stem cell (HSC) engraftment, it appears essential to establish niches for the donor HSCs by depleting the host HSCs. To date, this has been achievable only by nonselective treatments such as irradiation or chemotherapeutic drugs. An approach that is capable of more selectively depleting host HSCs is needed to widen the clinical application of HSCT. Here, we show in a clinically relevant nonhuman primate model that selective inhibition of B cell lymphoma 2 (Bcl-2) promoted hematopoietic chimerism and renal allograft tolerance after partial deletion of HSCs and effective peripheral lymphocyte deletion while preserving myeloid cells and regulatory T cells. Although Bcl-2 inhibition alone was insufficient to induce hematopoietic chimerism, the addition of a Bcl-2 inhibitor resulted in promotion of hematopoietic chimerism and renal allograft tolerance despite using only half of the dose of total body irradiation previously required. Selective inhibition of Bcl-2 is therefore a promising approach to induce hematopoietic chimerism without myelosuppression and has the potential to render HSCT more feasible for a variety of clinical indications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Massachusetts General Hospital, Department of Surgery, Harvard Medical School, Boston, MA 02114, USA.
- Massachusetts General Hospital, Department of Pathology, Harvard Medical School, Boston, MA 02114, USA.
- Massachusetts General Hospital, Department of Medicine, Harvard Medical School, Boston, M 02114, USA.
- Massachusetts General Hospital, Biostatistics Center, Boston, MA 02114, USA.
- Division of Nephrology, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.
- Department of Internal Medicine, Cantonal Hospital Graubuenden, 7000 Chur, Switzerland.
ORCID-Profile: Hajime Sasaki, Takayuki Hirose, Tetsu Oura, Ryo Otsuka, Ivy Rosales, David Ma, Grace Lassiter, Toshihide Tomosugi, Masatoshi Matsunami, Patrick M Reeves, Isabel Hanekamp, Samuel Schwartz, Thomas Fehr, Tatsuo Kawai
Förderung
- NIAID NIH HHS
Zitieren
APA
Sasaki, H., Hirose, T., Oura, T., Otsuka, R., Rosales, I., Ma, D., Lassiter, G., Karadagi, A., Tomosugi, T., Dehnadi, A., Matsunami, M., Raju Paul, S., Reeves, P. M., Hanekamp, I., Schwartz, S., Colvin, R. B., Lee, H., Spitzer, T. R., Cosimi, A. B., …, & Kawai, T. (2023). Selective Bcl-2 inhibition promotes hematopoietic chimerism and allograft tolerance without myelosuppression in nonhuman primates. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.add5318
Vancouver
Sasaki H, Hirose T, Oura T, Otsuka R, Rosales I, Ma D, et al. Selective Bcl-2 inhibition promotes hematopoietic chimerism and allograft tolerance without myelosuppression in nonhuman primates. Science Translational Medicine. 2023. doi:10.1126/scitranslmed.add5318
BibTeX
@article{Sasaki2023,
author = {Sasaki, Hajime and Hirose, Takayuki and Oura, Tetsu and Otsuka, Ryo and Rosales, Ivy and Ma, David and Lassiter, Grace and Karadagi, Ahmad and Tomosugi, Toshihide and Dehnadi, Abbas and Matsunami, Masatoshi and Raju Paul, Susan and Reeves, Patrick M and Hanekamp, Isabel and Schwartz, Samuel and Colvin, Robert B and Lee, Hang and Spitzer, Thomas R and Cosimi, A Benedict and Cippà, Pietro E and Fehr, Thomas and Kawai, Tatsuo},
title = {Selective Bcl-2 inhibition promotes hematopoietic chimerism and allograft tolerance without myelosuppression in nonhuman primates},
journal = {Science Translational Medicine},
year = {2023},
doi = {10.1126/scitranslmed.add5318}
}
EUVIMED